Suppr超能文献

通过 DLS 和 AF4-UV-MALS 对先进的纳米医学进行表征:在 HIV 纳米疫苗中的应用。

Advanced nanomedicine characterization by DLS and AF4-UV-MALS: Application to a HIV nanovaccine.

机构信息

Ultra Trace Analyses Aquitaine (UT2A/ADERA), Technopôle Hélioparc Pau-Pyrénées, 2 Avenue du Président Angot, PAU Cedex 9, 64053, France.

Ultra Trace Analyses Aquitaine (UT2A/ADERA), Technopôle Hélioparc Pau-Pyrénées, 2 Avenue du Président Angot, PAU Cedex 9, 64053, France.

出版信息

J Pharm Biomed Anal. 2020 Feb 5;179:113017. doi: 10.1016/j.jpba.2019.113017. Epub 2019 Nov 30.

Abstract

Nanoformulations are complex systems where physicochemical properties determine their therapeutic efficacy and safety. In the case of nanovaccines, particle size and shape play a crucial role on the immune response generated. Furthermore, the antigen's integrity is also a key aspect to control when producing a nanovaccine. The determination of all those physicochemical properties is still an analytical challenge and the lack of well-established methods hinders the access of new therapeutics to the market. In this work, robust methods for the characterization of a novel HIV nanoparticle-based vaccine produced in good manufacturing practice (GMPs)-like environment were developed. With slightly polydisperse particles (< 0.2) close to 180 nm of size, batch-mode Dynamic Light Scattering (DLS) was validated to be used as a quality control technique in the pilot production plant. In addition, a high size resolution method using Asymmetrical Flow Field Flow Fractionation (AF4) demonstrated its ability to determine not only size and size distribution but also shape modification across the size and accurate quantification of the free active ingredient. Results showed a monomodal distribution of particles from 60 to 700 nm, most of them (> 90%) with size lower than 250 nm, consistent with more traditional techniques, and revealed a slight change in the structure of the particles induced by the presence of the antigen. Finally, a batch to batch variability lower than 20% was obtained by both DLS and AF4 methods indicating that preparation method was highly reproducible.

摘要

纳米制剂是复杂的系统,其理化性质决定了其治疗效果和安全性。在纳米疫苗的情况下,颗粒大小和形状对产生的免疫反应起着至关重要的作用。此外,抗原的完整性也是生产纳米疫苗时需要控制的关键方面。所有这些理化性质的确定仍然是一个分析挑战,缺乏完善的方法阻碍了新疗法进入市场。在这项工作中,开发了用于表征在良好生产规范(GMP)样环境中生产的新型 HIV 纳米颗粒疫苗的稳健方法。具有轻微多分散性(<0.2)、接近 180nm 大小的批量模式动态光散射(DLS)被验证可作为中试生产工厂的质量控制技术。此外,使用不对称流场流分离(AF4)的高尺寸分辨率方法证明了其不仅能够确定尺寸和尺寸分布,还能够确定跨尺寸的形状变化以及游离活性成分的准确定量。结果表明,从 60 到 700nm 的颗粒呈现单模态分布,其中大多数(>90%)颗粒的尺寸小于 250nm,与更传统的技术一致,并显示出由于抗原存在而导致的颗粒结构的轻微变化。最后,通过 DLS 和 AF4 方法均获得低于 20%的批间变异性,表明制备方法具有高度重现性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验